Repligen Corporation (RGEN) Revenue by Segment
Repligen revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Repligen's largest product or service was Product, with $204.09 million or 100% of revenue, up 11.9% from a year earlier. Next: Royalty (under 1%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Repligen Corporation
RGEN
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Repligen revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Product | $204.1M | $194.2M | $188.8M | $182.3M | 100% |
| Royalty | $43,000 | $44,000 | $39,000 | $37,000 | under 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Repligen?
Product: $204.09 million, or 100% of revenue, in Q2 fiscal 2026.
What are Repligen's main products and services?
By revenue in Q2 fiscal 2026: Product (100%) and Royalty (under 1%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
